Welch & Forbes LLC Has $2.53 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Welch & Forbes LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 0.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,534 shares of the biopharmaceutical company’s stock after selling 364 shares during the quarter. Welch & Forbes LLC’s holdings in Gilead Sciences were worth $2,528,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in GILD. Joseph P. Lucia & Associates LLC acquired a new position in Gilead Sciences during the 1st quarter valued at $25,000. FSB Premier Wealth Management Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at $28,000. Capital Advisors Ltd. LLC raised its stake in Gilead Sciences by 127.6% during the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 250 shares during the last quarter. Artemis Wealth Advisors LLC acquired a new position in Gilead Sciences during the 1st quarter valued at $32,000. Finally, Mystic Asset Management Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 80.16% of the company’s stock.

Shares of NASDAQ:GILD opened at $62.34 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $74.12. The company’s 50-day moving average price is $61.98 and its two-hundred day moving average price is $63.59. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The firm has a market cap of $78.19 billion, a P/E ratio of 17.41, a P/E/G ratio of 0.63 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. The company’s revenue was up 2.6% on a year-over-year basis. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.59 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th were issued a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 4.68%. The ex-dividend date was Tuesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 81.56%.

Several brokerages have issued reports on GILD. Barclays lowered their price target on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a report on Thursday, March 10th. Wells Fargo & Company lowered their price target on shares of Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 22nd. Piper Sandler lowered their price target on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating on the stock in a report on Monday, May 16th. StockNews.com began coverage on shares of Gilead Sciences in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, SVB Leerink began coverage on shares of Gilead Sciences in a report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $72.07.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.